Con: The Role of Currently Available Biomarkers Genomics in Risk Stratification of Prostate Cancer

Rate:
5
added:
5 years ago
views:
445
specialty:
Urology

Case description

Alan H. Bryce, MD, Chair of the Division of Hematology and Medical Oncology and Assistant Professor of Medicine at the Mayo Clinic in Phoenix, Arizona, argues that although germline testing is beneficial, other biomarker tests have inconsistent results for prostate cancer patients. These biomarker tests help manage the psychological part of fighting cancer by overcoming indecisiveness and giving patients a false sense of security. He argues that results provided by biomarkers can lead to misinterpretations and, therefore, biomarkers should be evaluated together with other tumor-related features and patient characteristics.

tags: biomarker tests PCA prostate cancer


This user also sharing

Recommended

show more